Not exact matches
Upper respiratory tract inflammatory diseases such
as asthma and COPD affect more than half a billion people worldwide and are
characterized by chronic inflammation that is aggravated by respiratory pathogens such
as NTHi.
As part of a large NIH - funded effort to develop immunotherapies for this allergy (the Inner City
Asthma Consortium, or ICAC), the Sette lab has thus identified dominant epitopes to
characterize T cell responses in allergic individuals before and after immunotherapy.
Their recent study, published in PNAS (3),
characterizes the mechanism of action of a smooth muscle myosin inhibitor, CK - 2018571, that induces smooth muscle relaxation and can be used to treat diseases involving smooth muscle hypercontractility, such
as asthma and chronic obstructive pulmonary disease.
My laboratory aims to identify,
characterize and validate lncRNA - driven pathways active in allergy - driving helper T cells and airway epithelial cells that could hold promise
as therapeutic targets in altering the aberrant immune responses underlying
asthma.